Multiple Sclerosis Clinical Trials

Our center is leading or participating in several clinical trials for both relapsing remitting and primary progressive MS. Our team is particularly dedicated to finding better treatments for progressive MS. Below are some of the MS clinical trials currently active at Johns Hopkins.

Our Active Trials

Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis (CAVS-MS) Identifier: NCT04495556
Principal Investigator: Peter Calabresi, M.D.

The Use of Technology to Improve MS Clinical Trials and Patient Care Identifier: NCT02454907
Principal Investigator: Ellen Mowry, M.D.

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS) Identifier: NCT03500328
Principal Investigator: Ellen Mowry, M.D., Scott Newsome, D.O.

Ocrelizumab Effects on the Metabolome in MS Identifier: NCT03873389
Principal Investigator: Pavan Bhargava, M.D.

Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis Identifier: NCT04261790
Principal Investigator: Bardia Nourbakhsh, M.A.S., M.D.

Additional Clinical Trials Resources

Genes Linked to Most Severe Symptoms of Multiple Sclerosis

To determine factors linked to the most debilitating forms of MS, Johns Hopkins researchers have identified three so-called “complement system” genes that appear to play a role in MS vision loss. The researchers were able to single out these genes by using DNA from MS patients along with high-tech retinal scanning. These genes could serve as markers for monitoring and predicting progression and severity of MS.